SELLAS Life Sciences Group (SLS) Cash from Financing Activities: 2011-2024
Historic Cash from Financing Activities for SELLAS Life Sciences Group (SLS) over the last 7 years, with Sep 2024 value amounting to $19.7 million.
- SELLAS Life Sciences Group's Cash from Financing Activities rose 36362.96% to $19.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $50.1 million, marking a year-over-year increase of 152.47%. This contributed to the annual value of $46.8 million for FY2024, which is 109.54% up from last year.
- Latest data reveals that SELLAS Life Sciences Group reported Cash from Financing Activities of $19.7 million as of Q3 2024, which was up 4,656.04% from $414,000 recorded in Q2 2024.
- SELLAS Life Sciences Group's 5-year Cash from Financing Activities high stood at $26.6 million for Q1 2024, and its period low was -$29,000 during Q2 2023.
- Over the past 3 years, SELLAS Life Sciences Group's median Cash from Financing Activities value was $929,000 (recorded in 2022), while the average stood at $8.5 million.
- The largest annual percentage gain for SELLAS Life Sciences Group's Cash from Financing Activities in the last 5 years was 40,121.28% (2023), contrasted with its biggest fall of 100.13% (2023).
- SELLAS Life Sciences Group's Cash from Financing Activities (Quarterly) stood at $23.7 million in 2020, then slumped by 99.79% to $50,000 in 2021, then surged by 1,758.00% to $929,000 in 2022, then surged by 264.48% to $3.4 million in 2023, then soared by 36,362.96% to $19.7 million in 2024.
- Its Cash from Financing Activities was $19.7 million in Q3 2024, compared to $414,000 in Q2 2024 and $26.6 million in Q1 2024.